［1］Berger J, Moller DE. The mechanisms of action of PPARs［J］.Annu Rev Med, 2002,53:409. ［2］Wurtz JM, Bourguet W, Renaud JP,et al. A canonical structure for the ligandbinding domain of nuclear receptors［J］.Nature Structural Biology, 1996,3(1):87. ［3］Xu HE, Lambert MH, Montana VG,et al. Structural determinants of ligand binding selectivity between the peroxisome proliferatoractivated receptors［J］.Proc Nati Acad Sci USA, 2001,98(24):13919. ［4］Kliewer SA, Sundseth SS, Jones SA,et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferatoractivated receptors alpha and gamma［J］.Proc Nati Acad Sci USA, 1997,2994(9):4318. ［5］Zhu Y, Qi C, Calandra C,et al. Cloning and identification of mouse steroid receptor coactivator1 (mSRC1), as a coactivator of peroxisome proliferatoractivated receptor gamma［J］.Gene Expression, 1996,6(3):185. ［6］Zhu Y, Qi C, Jain S,et al. Isolation and characterization of PBP, a protein that interacts with peroxisome proliferatoractivated receptor［J］.J Biol Chem, 1997,272(41):25500. ［7］Heery DM, Kalkhoven E, Hoare S,et al. A signature motif in transcriptional coactivators mediates binding to nuclear receptors［J］.Nature, 1997,387(6634):733. ［8］Oberkofler H, Esterbauer H, Linnemayr V, et al. Peroxisome proliferatorsactivated receptor gamma coactivator1 recruitment regulated PPAR subtype specificity［J］.J Biol Chem, 2002,277(19):17650. ［9］Oberfield JL, Collins JL, Holmes CP,et al. A peroxisome proliferatoractivated receptor gamma ligand inhibits adipocyte differentiation［J］.Proc Nati Acad Sci USA, 1999,96(11):6102. ［10］Wurch T, Junquero D, Delhon A,et al. Pharmacological analysis of wildtype alpha, gamma and delta subtypes of the human peroxisome proliferatoractivated receptor［J］.Naunyn Schmiedebergs Arch Pharmacol, 2002,365(2):133. ［11］Yu K, Bayona W, Kallen CB,et al. Differential activation of peroxisome proliferatoractivated receptors by eicosanoids［J］.J Biol Chem, 1995,270(41):23975. ［12］ Brown PJ, Winegar DA, Plunket KD,et al. A ureidothioisobutyric acid (GW9578) is a subtypeselective PPARalpha agonist with potent lipidlowering activity［J］.J Med Chem, 1999,42(19):3785. ［13］Berjer J, Leibowitz MD, Doebber TW,et al. Novel PPAR gamma and PPAR beta Ligands produce distinct biological effects［J］.J Biol Chem, 1999,274(10):6718. ［14］Willson TM, Brown PJ, Sternbach DD,et al. The PPARs: from orphan receptors to drug discovery［J］.J Med Chem, 2000,43(4):527. ［15］Oliver WR Jr, Shenk JL, Snaith MR,et al. A selective peroxisome proliferatoractivated receptor delta agonist promotes reverse cholesterol transport［J］.Proc Nati Acad Sci USA, 2001,98(9):5306. ［16］Brown PJ, SmithOliver TA, Charifson PS,et al. Identification of peroxisome proliferatoractivated receptor ligands from a biased chemical library［J］.Chem Biol, 1997,4(12):909. ［17］Murakami K, Tobe K, Ide T,et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferatoractivated receptoralpha (PPARalpha) and PPARgamma: effect of PPARalpha activation on abnormal lipid metabolism in liver of Zucker fatty rats［J］.Diabetes, 1998,47(12):1841. ［18］Leesnitzer LM, Parks DJ, Bledsoe RK,et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662［J］.Biochemistry, 2002,41(21):6640. ［19］Lehmann JM, Moore LB, SmithOliver TA,et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferatoractivated receptor gamma (PPAR gamma)［J］.J Biol Chem, 1995,270(22):12953. ［20］Berger J, Leibowitz MD, Doebber TW,et al. Novel peroxisome proliferatoractivated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects［J］.J Biol Chem, 1999,274(10):6718. ［21］Berger J, Bailey P, Biswas C,et al. Thiazolidinediones produce a conformational change in peroxisomal proliferatoractivated receptorgamma: binding and activation correlate with antidiabetic actions in db/db mice［J］.Endocrinology, 1996,137(10):4189. ［22］Elbrecht A, Chen Y, Adams A,et al. L 764406 is a partial agonist of human peroxisome proliferatoractivated receptor gamma. The role of Cys313 in ligand binding［J］.J Biol Chem, 1999,274(12):7913. ［23］Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferatoractivated receptors alpha and delta［J］.Proc Nati Acad Sci USA, 1997,94(9):4312. ［24］Dowell P, Peterson VJ, Zabriskie TM,et al. Ligandinduced peroxisome proliferatoractivated receptor alpha conformational change［J］.J Biol Chem, 1997,272(3):2013. ［25］Lin Q, Ruuska SE, Shaw NS,et al. Ligand selectivity of the peroxisome proliferatoractivated receptor alpha［J］.Biochemistry, 1999,38(1):185. ［26］Cesario RM, Klausing K, Razzaghi H,et al. The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo［J］.Mol Endocrinol, 2001,15(8):1360.